An Emerging Role of Glucagon-Like Peptide-1 in Preventing Advanced-Glycation-End-Product-Mediated Damages in Diabetes
Glucagon-like peptide-1 (GLP-1) is a gut hormone produced in the intestinal epithelial endocrine L cells by differential processing of the proglucagon gene. Released in response to the nutrient ingestion, GLP-1 plays an important role in maintaining glucose homeostasis. GLP-1 has been shown to regul...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2013/591056 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564396240404480 |
|---|---|
| author | Alessandra Puddu François Mach Alessio Nencioni Giorgio Luciano Viviani Fabrizio Montecucco |
| author_facet | Alessandra Puddu François Mach Alessio Nencioni Giorgio Luciano Viviani Fabrizio Montecucco |
| author_sort | Alessandra Puddu |
| collection | DOAJ |
| description | Glucagon-like peptide-1 (GLP-1) is a gut hormone produced in the intestinal epithelial endocrine L cells by differential processing of the proglucagon gene. Released in response to the nutrient ingestion, GLP-1 plays an important role in maintaining glucose homeostasis. GLP-1 has been shown to regulate blood glucose levels by stimulating glucose-dependent insulin secretion and inhibiting glucagon secretion, gastric emptying, and food intake. These antidiabetic activities highlight GLP-1 as a potential therapeutic molecule in the clinical management of type 2 diabetes, (a disease characterized by progressive decline of beta-cell function and mass, increased insulin resistance, and final hyperglycemia). Since chronic hyperglycemia contributed to the acceleration of the formation of Advanced Glycation End-Products (AGEs, a heterogeneous group of compounds derived from the nonenzymatic reaction of reducing sugars with free amino groups of proteins implicated in vascular diabetic complications), the administration of GLP-1 might directly counteract diabetes pathophysiological processes (such as pancreatic β-cell dysfunction). This paper outlines evidence on the protective role of GLP-1 in preventing the deleterious effects mediated by AGEs in type 2 diabetes. |
| format | Article |
| id | doaj-art-2d2fbd5e56604f94a4e2c6f062a5aa40 |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-2d2fbd5e56604f94a4e2c6f062a5aa402025-02-03T01:11:06ZengWileyMediators of Inflammation0962-93511466-18612013-01-01201310.1155/2013/591056591056An Emerging Role of Glucagon-Like Peptide-1 in Preventing Advanced-Glycation-End-Product-Mediated Damages in DiabetesAlessandra Puddu0François Mach1Alessio Nencioni2Giorgio Luciano Viviani3Fabrizio Montecucco4Department of Internal Medicine, University of Genoa, Viale Benedetto XV 6, 16132 Genoa, ItalyDivision of Cardiology, Geneva University Hospitals, Faculty of Medicine, Foundation for Medical Researches, Avenue de la Roseraie 64, 1211 Geneva, SwitzerlandDepartment of Internal Medicine, University of Genoa, Viale Benedetto XV 6, 16132 Genoa, ItalyDepartment of Internal Medicine, University of Genoa, Viale Benedetto XV 6, 16132 Genoa, ItalyDivision of Cardiology, Geneva University Hospitals, Faculty of Medicine, Foundation for Medical Researches, Avenue de la Roseraie 64, 1211 Geneva, SwitzerlandGlucagon-like peptide-1 (GLP-1) is a gut hormone produced in the intestinal epithelial endocrine L cells by differential processing of the proglucagon gene. Released in response to the nutrient ingestion, GLP-1 plays an important role in maintaining glucose homeostasis. GLP-1 has been shown to regulate blood glucose levels by stimulating glucose-dependent insulin secretion and inhibiting glucagon secretion, gastric emptying, and food intake. These antidiabetic activities highlight GLP-1 as a potential therapeutic molecule in the clinical management of type 2 diabetes, (a disease characterized by progressive decline of beta-cell function and mass, increased insulin resistance, and final hyperglycemia). Since chronic hyperglycemia contributed to the acceleration of the formation of Advanced Glycation End-Products (AGEs, a heterogeneous group of compounds derived from the nonenzymatic reaction of reducing sugars with free amino groups of proteins implicated in vascular diabetic complications), the administration of GLP-1 might directly counteract diabetes pathophysiological processes (such as pancreatic β-cell dysfunction). This paper outlines evidence on the protective role of GLP-1 in preventing the deleterious effects mediated by AGEs in type 2 diabetes.http://dx.doi.org/10.1155/2013/591056 |
| spellingShingle | Alessandra Puddu François Mach Alessio Nencioni Giorgio Luciano Viviani Fabrizio Montecucco An Emerging Role of Glucagon-Like Peptide-1 in Preventing Advanced-Glycation-End-Product-Mediated Damages in Diabetes Mediators of Inflammation |
| title | An Emerging Role of Glucagon-Like Peptide-1 in Preventing Advanced-Glycation-End-Product-Mediated Damages in Diabetes |
| title_full | An Emerging Role of Glucagon-Like Peptide-1 in Preventing Advanced-Glycation-End-Product-Mediated Damages in Diabetes |
| title_fullStr | An Emerging Role of Glucagon-Like Peptide-1 in Preventing Advanced-Glycation-End-Product-Mediated Damages in Diabetes |
| title_full_unstemmed | An Emerging Role of Glucagon-Like Peptide-1 in Preventing Advanced-Glycation-End-Product-Mediated Damages in Diabetes |
| title_short | An Emerging Role of Glucagon-Like Peptide-1 in Preventing Advanced-Glycation-End-Product-Mediated Damages in Diabetes |
| title_sort | emerging role of glucagon like peptide 1 in preventing advanced glycation end product mediated damages in diabetes |
| url | http://dx.doi.org/10.1155/2013/591056 |
| work_keys_str_mv | AT alessandrapuddu anemergingroleofglucagonlikepeptide1inpreventingadvancedglycationendproductmediateddamagesindiabetes AT francoismach anemergingroleofglucagonlikepeptide1inpreventingadvancedglycationendproductmediateddamagesindiabetes AT alessionencioni anemergingroleofglucagonlikepeptide1inpreventingadvancedglycationendproductmediateddamagesindiabetes AT giorgiolucianoviviani anemergingroleofglucagonlikepeptide1inpreventingadvancedglycationendproductmediateddamagesindiabetes AT fabriziomontecucco anemergingroleofglucagonlikepeptide1inpreventingadvancedglycationendproductmediateddamagesindiabetes AT alessandrapuddu emergingroleofglucagonlikepeptide1inpreventingadvancedglycationendproductmediateddamagesindiabetes AT francoismach emergingroleofglucagonlikepeptide1inpreventingadvancedglycationendproductmediateddamagesindiabetes AT alessionencioni emergingroleofglucagonlikepeptide1inpreventingadvancedglycationendproductmediateddamagesindiabetes AT giorgiolucianoviviani emergingroleofglucagonlikepeptide1inpreventingadvancedglycationendproductmediateddamagesindiabetes AT fabriziomontecucco emergingroleofglucagonlikepeptide1inpreventingadvancedglycationendproductmediateddamagesindiabetes |